Ars Pharmaceuticals Earnings Call Highlights Neffy’s Early Traction

Ars Pharmaceuticals, Inc. ((SPRY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Ars Pharmaceuticals’ latest earnings call painted a cautiously optimistic picture, with early commercial traction for neffy offset by heavy spending and structural hurdles in the epinephrine market. Management highlighted growing awareness, strong prescriber engagement and a solid cash runway, arguing these positives outweigh near-term margin pressure and access friction.

First Full Year Commercial Revenue

Ars reported its first full commercial year with $72.2 million in U.S. net product revenue from neffy and $84.3 million in total revenue, including collaboration and supply income. The results show meaningful initial uptake for a new product in a mature, refill-driven category, but the company is still far from scale relative to its cost base.

Strong Cash Position

Year-end cash, cash equivalents and short-term investments stood at $245 million, giving Ars a comfortable liquidity buffer. Management believes this cash is sufficient to fund U.S. commercial expansion and development plans through the point of expected cash-flow breakeven.

Prescriber Adoption and Repeat Writing

More than 22,500 health care providers prescribed neffy by the end of 2025, with roughly half writing repeat prescriptions. Around 80% of scripts are coming from high-volume allergists and pediatricians in the top deciles, underscoring the company’s focus on targeted, high-yield accounts.

DTC Awareness Lift

Direct-to-consumer campaigns have dramatically lifted neffy’s brand profile, with aided awareness rising from about 20% before the campaign to roughly 60% afterward. Approximately 55% of caregivers and patients recall seeing a neffy advertisement, a level the company says exceeds typical industry benchmarks.

Digital Conversion and Get neffy on Us Traction

The company’s digital hub, getneffy.com, has already driven about 10% of neffy prescriptions by offering virtual visits and a zero co-pay option for eligible insured patients. This online pathway is designed to reduce in-office friction and capture consumers who respond to DTC advertising but prefer a streamlined digital experience.

Real-World Effectiveness Data

Real-world data from the neffy Experience program suggest that about 90% of patients experiencing anaphylaxis were effectively treated with a single dose. Management stressed that these outcomes align with injection-based epinephrine products, reinforcing confidence in neffy’s safety and efficacy profile.

Commercial Coverage Expansion

Ars reported that around 93% of commercially insured lives now have access to neffy, though some plans still impose barriers. Medicaid coverage is unrestricted in eight states, and the company is continuing active negotiations with payers to further improve access and reduce utilization hurdles.

Operational Plan to Increase Field Intensity

To deepen penetration in high-volume accounts, Ars plans to expand its salesforce from 106 to 150 representatives beginning in the second quarter of 2026. Crucially, this larger field presence will be funded by reallocating existing commercial resources, aiming to keep the 2026 SG&A run rate broadly in line with 2025 levels.

International and Pipeline Progress

Outside the U.S., international partners are pushing ahead with regulatory approvals and launch preparations in Europe, China, Japan and Australia for 2026. On the pipeline side, a Phase IIb program targeting chronic spontaneous urticaria flares remains on track, with interim data expected in the second half of 2026 and a Phase III study slated to begin in mid-2027.

High SG&A Relative to Revenue

Selling, general and administrative expenses reached $230.1 million in 2025, dwarfing the $72.2 million in U.S. net product revenue and underscoring a sizable operating loss. Management framed this as a deliberate investment phase, but investors will be watching closely for revenue growth to begin catching up with the elevated cost structure.

Gross-to-Net and Revenue Predictability

The year-end gross-to-net adjustment sat in the low- to mid-50% range, meaning roughly half of gross sales are being eaten up by discounts, rebates and other allowances. Ars is targeting about 50% at steady state, yet this level of discounting will keep pressure on net realized revenue and complicate forecasting.

Prior Authorization and Access Friction

Only about 57% of covered lives can access neffy without prior authorization, while plans that do require prior authorization show approval rates of roughly 55%. These added steps introduce administrative friction that can slow prescribing momentum in a category where speed and convenience are crucial.

Refill-Driven Market Dynamics Delay Growth

The epinephrine market is heavily driven by refills, which account for around half of all prescriptions and are often e-prescribed without a new office visit. As a new entrant, neffy currently relies mostly on new prescriptions, so Ars does not expect the full benefit of refill-driven renewals until later in 2026 and into 2027.

Renewal and Retention Headwinds in Market

Citing IQVIA data, management noted that only 31% to 39% of refill prescriptions in the broader market are renewed after 12 to 24 months. This relatively low retention rate implies ongoing patient turnover, meaning Ars must sustain high levels of conversion and engagement just to maintain, let alone grow, its installed base.

Dependence on DTC and Field Execution

The company’s growth strategy leans heavily on DTC and field promotion, with roughly $100 million spent in 2025 on consumer and health care professional advertising and a similar budget expected in 2026. For shareholders, the key question is whether this sizable marketing spend will continue to translate into durable prescription growth and share gains.

Seasonality and Inventory Sensitivity

Management highlighted that neffy sales are subject to seasonal patterns, including deductible resets and back-to-school demand, which can shift prescriptions across quarters. Inventory levels and days on hand are being closely monitored, but these dynamics add further variability and execution risk around peak selling periods.

2026 Guidance and Forward-Looking Priorities

Looking ahead, Ars outlined an execution-focused 2026 plan that keeps SG&A roughly flat while reallocating spend to expand the field force and optimize media. Priorities include improving access, driving adoption among high-volume prescribers, boosting digital conversion, and capturing the expected refill tailwind in late 2026 and 2027, alongside steady international and pipeline progress.

Ars Pharmaceuticals’ earnings call presented a story of early commercial success and strong balance sheet support, tempered by high costs and structural obstacles in a complex market. If the company can convert its awareness gains, payer negotiations and field expansion into sustained prescription growth and better leverage on SG&A, the investment in neffy’s launch could start to pay off in the coming years.